stoxline Quote Chart Rank Option Currency Glossary
  
Arcus Biosciences, Inc. (RCUS)
18.88  0.67 (3.68%)    03-28 16:00
Open: 18.3
High: 19.11
Volume: 744,390
  
Pre. Close: 18.21
Low: 18.18
Market Cap: 1,716(M)
Technical analysis
2024-03-28 4:53:54 PM
Short term     
Mid term     
Targets 6-month :  23.72 1-year :  27.7
Resists First :  20.3 Second :  23.72
Pivot price 17.85
Supports First :  17.7 Second :  16.1
MAs MA(5) :  17.32 MA(20) :  18.1
MA(100) :  16.75 MA(250) :  18.1
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  53.2 D(3) :  30.1
RSI RSI(14): 57.3
52-week High :  25.46 Low :  12.94
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RCUS ] has closed below upper band by 22.2%. Bollinger Bands are 1.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 19.11 - 19.18 19.18 - 19.24
Low: 17.99 - 18.08 18.08 - 18.15
Close: 18.74 - 18.86 18.86 - 18.97
Company Description

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Headline News

Wed, 27 Mar 2024
Arcus Biosciences (NYSE:RCUS) Shares Up 7.6% - MarketBeat

Wed, 27 Mar 2024
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Wed, 27 Mar 2024
Analysts Set Arcus Biosciences, Inc. (NYSE:RCUS) Target Price at $41.25 - MarketBeat

Wed, 27 Mar 2024
Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases - Yahoo Movies Canada

Mon, 25 Mar 2024
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by American Century Companies Inc. - Defense World

Wed, 20 Mar 2024
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 91 (M)
Shares Float 54 (M)
Held by Insiders 41.1 (%)
Held by Institutions 59.9 (%)
Shares Short 7,680 (K)
Shares Short P.Month 7,000 (K)
Stock Financials
EPS -4.16
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.11
Profit Margin -262.4 %
Operating Margin -293.6 %
Return on Assets (ttm) -17.5 %
Return on Equity (ttm) -54.9 %
Qtrly Rev. Growth -8.9 %
Gross Profit (p.s.) 0
Sales Per Share 1.28
EBITDA (p.s.) -3.66
Qtrly Earnings Growth 0 %
Operating Cash Flow -306 (M)
Levered Free Cash Flow -188 (M)
Stock Valuations
PE Ratio -4.55
PEG Ratio 0
Price to Book value 3.08
Price to Sales 14.66
Price to Cash Flow -5.61
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android